FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078330295> ?p ?o ?g. }

• W2078330295 endingPage "A136" @default.
• W2078330295 startingPage "A136" @default.
• W2078330295 abstract "Dexlansoprazole, a once-daily proton pump inhibitor (PPI) in a Dual Delayed Release formulation has demonstrated efficacy in a phase 3b study in maintaining symptom control among gastroesophageal reflux disease (GERD) patients previously controlled on twice daily (BID) PPIs. A pharmacy budget impact model (BIM) from a US payer perspective was developed to assess the impact of switching GERD patients from BID PPIs to QD dexlansoprazole over a three-year period. An excel-based BIM on a hypothetical plan of 1 million members was developed. Based on published literature, 28% of members had GERD, among which 57% were prescribed PPI therapy. Among these, 74%, 23% and 3% of patients were on QD, BID and as needed PPI therapy, respectively. The proportion of patients switching from BID PPI to QD dexlansoprazole and efficacy of dexlansoprazole in achieving symptom control among those patients was assumed to range from 84%-88% based on the results of the phase 3b trial. Market share of PPIs and drug costs were derived using internally available data. The market share of dexlansoprazole in year 1 was 4.23% and 8.44% pre- and post-switching, respectively. Model outcomes for years 1, 2 and 3 included: net total and per member per month (PMPM) pharmacy savings. The net pharmacy saving from switching to QD dexlansoprazole was estimated to be $7.9, $6.4 & $5.9 million for years 1, 2, & 3, respectively. PMPM pharmacy cost savings ranged from $0.66 in year 1 to $0.50 in year 3. The model results were most sensitive to cost of esomeprazole, proportion of GERD patients on PPI, prevalence of the disease, and proportion of patients switching from BID esomeprazole to QD dexlansoprazole. Based on the economic model, switching GERD patients from twice daily PPIs to QD dexlansoprazole may generate cost savings for US health plans." @default.
• W2078330295 created "2016-06-24" @default.
• W2078330295 creator A5011388259 @default.
• W2078330295 creator A5033435809 @default.
• W2078330295 creator A5059525894 @default.
• W2078330295 creator A5076341878 @default.
• W2078330295 date "2012-06-01" @default.
• W2078330295 modified "2023-09-28" @default.
• W2078330295 title "PGI9 Impact of Switching Patients from Twice Daily Proton Pump Inhibitors to Once Daily Dexlansoprazole" @default.
• W2078330295 doi "https://doi.org/10.1016/j.jval.2012.03.736" @default.
• W2078330295 hasPublicationYear "2012" @default.
• W2078330295 type Work @default.
• W2078330295 sameAs 2078330295 @default.
• W2078330295 citedByCount "0" @default.
• W2078330295 crossrefType "journal-article" @default.
• W2078330295 hasAuthorship W2078330295A5011388259 @default.
• W2078330295 hasAuthorship W2078330295A5033435809 @default.
• W2078330295 hasAuthorship W2078330295A5059525894 @default.
• W2078330295 hasAuthorship W2078330295A5076341878 @default.
• W2078330295 hasBestOaLocation W20783302951 @default.
• W2078330295 hasConcept C104863432 @default.
• W2078330295 hasConcept C126322002 @default.
• W2078330295 hasConcept C159110408 @default.
• W2078330295 hasConcept C2777014526 @default.
• W2078330295 hasConcept C2777498785 @default.
• W2078330295 hasConcept C2778715759 @default.
• W2078330295 hasConcept C2779134260 @default.
• W2078330295 hasConcept C2781025758 @default.
• W2078330295 hasConcept C43270747 @default.
• W2078330295 hasConcept C71924100 @default.
• W2078330295 hasConceptScore W2078330295C104863432 @default.
• W2078330295 hasConceptScore W2078330295C126322002 @default.
• W2078330295 hasConceptScore W2078330295C159110408 @default.
• W2078330295 hasConceptScore W2078330295C2777014526 @default.
• W2078330295 hasConceptScore W2078330295C2777498785 @default.
• W2078330295 hasConceptScore W2078330295C2778715759 @default.
• W2078330295 hasConceptScore W2078330295C2779134260 @default.
• W2078330295 hasConceptScore W2078330295C2781025758 @default.
• W2078330295 hasConceptScore W2078330295C43270747 @default.
• W2078330295 hasConceptScore W2078330295C71924100 @default.
• W2078330295 hasIssue "4" @default.
• W2078330295 hasLocation W20783302951 @default.
• W2078330295 hasOpenAccess W2078330295 @default.
• W2078330295 hasPrimaryLocation W20783302951 @default.
• W2078330295 hasRelatedWork W2031067686 @default.
• W2078330295 hasRelatedWork W2055941305 @default.
• W2078330295 hasRelatedWork W2072837274 @default.
• W2078330295 hasRelatedWork W2087216493 @default.
• W2078330295 hasRelatedWork W2132899763 @default.
• W2078330295 hasRelatedWork W2169338618 @default.
• W2078330295 hasRelatedWork W2391460296 @default.
• W2078330295 hasRelatedWork W2499203240 @default.
• W2078330295 hasRelatedWork W4254175882 @default.
• W2078330295 hasRelatedWork W4302499816 @default.
• W2078330295 hasVolume "15" @default.
• W2078330295 isParatext "false" @default.
• W2078330295 isRetracted "false" @default.
• W2078330295 magId "2078330295" @default.
• W2078330295 workType "article" @default.